Original article
Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement
Análisis coste-efectividad de apixaban frente a dabigatrán en la prevención de la tromboembolia venosa en pacientes intervenidos de artroplastia total de rodilla o de cadera
J.F. Gómez-Cerezoa, I. Gómez-Arrayásb, C. Suárez-Fernándezc, L. Betegón-Nicolásd, M. de Salas-Cansadoe, C. Rubio-Terrésf,
Corresponding author
a Servicio de Medicina Interna, Hospital Universitario Infanta Sofía, Madrid, Spain
b Servicio de Traumatología y Cirugía Ortopédica, Hospital Ruber Internacional, Madrid, Spain
c Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, Spain
d Bristol-Myers Squibb España, Madrid, Spain
e Pfizer España, Madrid, Spain
f Health Value, Madrid, Spain
Read
4586
Timeswas read the article
1537
Total PDF
3049
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 33 | 18 | 51 |
| 2025 11 | 79 | 71 | 150 |
| 2025 10 | 61 | 40 | 101 |
| 2025 9 | 62 | 31 | 93 |
| 2025 8 | 92 | 20 | 112 |
| 2025 7 | 124 | 13 | 137 |
| 2025 6 | 93 | 12 | 105 |
| 2025 5 | 49 | 12 | 61 |
| 2025 4 | 54 | 5 | 59 |
| 2025 3 | 51 | 12 | 63 |
| 2025 2 | 30 | 7 | 37 |
| 2025 1 | 23 | 5 | 28 |
| 2024 12 | 24 | 8 | 32 |
| 2024 11 | 24 | 5 | 29 |
| 2024 10 | 12 | 12 | 24 |
| 2024 9 | 21 | 11 | 32 |
| 2024 8 | 39 | 12 | 51 |
| 2024 7 | 22 | 9 | 31 |
| 2024 6 | 21 | 10 | 31 |
| 2024 5 | 21 | 13 | 34 |
| 2024 4 | 52 | 34 | 86 |
| 2024 3 | 53 | 10 | 63 |
| 2024 2 | 33 | 9 | 42 |
| 2024 1 | 69 | 12 | 81 |
| 2023 12 | 23 | 10 | 33 |
| 2023 11 | 15 | 10 | 25 |
| 2023 10 | 26 | 36 | 62 |
| 2023 9 | 24 | 13 | 37 |
| 2023 8 | 21 | 21 | 42 |
| 2023 7 | 16 | 19 | 35 |
| 2023 6 | 36 | 17 | 53 |
| 2023 5 | 46 | 29 | 75 |
| 2023 4 | 47 | 7 | 54 |
| 2023 3 | 26 | 12 | 38 |
| 2023 2 | 18 | 22 | 40 |
| 2023 1 | 16 | 14 | 30 |
| 2022 12 | 19 | 11 | 30 |
| 2022 11 | 14 | 21 | 35 |
| 2022 10 | 19 | 17 | 36 |
| 2022 9 | 22 | 30 | 52 |
| 2022 8 | 18 | 12 | 30 |
| 2022 7 | 14 | 13 | 27 |
| 2022 6 | 32 | 14 | 46 |
| 2022 5 | 20 | 18 | 38 |
| 2022 4 | 26 | 17 | 43 |
| 2022 3 | 23 | 19 | 42 |
| 2022 2 | 24 | 18 | 42 |
| 2022 1 | 19 | 15 | 34 |
| 2021 12 | 20 | 10 | 30 |
| 2021 11 | 21 | 26 | 47 |
| 2021 10 | 16 | 13 | 29 |
| 2021 9 | 18 | 15 | 33 |
| 2021 8 | 26 | 18 | 44 |
| 2021 7 | 21 | 11 | 32 |
| 2021 6 | 14 | 15 | 29 |
| 2021 5 | 17 | 9 | 26 |
| 2021 4 | 27 | 14 | 41 |
| 2021 3 | 31 | 14 | 45 |
| 2021 2 | 12 | 12 | 24 |
| 2021 1 | 14 | 15 | 29 |
| 2020 12 | 1 | 0 | 1 |
| 2020 11 | 0 | 7 | 7 |
| 2020 10 | 0 | 3 | 3 |
| 2020 9 | 0 | 8 | 8 |
| 2020 8 | 0 | 3 | 3 |
| 2020 7 | 0 | 5 | 5 |
| 2020 6 | 0 | 2 | 2 |
| 2020 5 | 0 | 7 | 7 |
| 2020 4 | 0 | 6 | 6 |
| 2020 3 | 0 | 5 | 5 |
| 2020 2 | 0 | 34 | 34 |
| 2020 1 | 0 | 17 | 17 |
| 2019 12 | 0 | 17 | 17 |
| 2019 11 | 0 | 12 | 12 |
| 2019 10 | 0 | 5 | 5 |
| 2019 9 | 0 | 6 | 6 |
| 2019 8 | 0 | 5 | 5 |
| 2019 7 | 0 | 11 | 11 |
| 2019 6 | 0 | 21 | 21 |
| 2019 5 | 0 | 34 | 34 |
| 2019 4 | 0 | 44 | 44 |
| 2019 3 | 0 | 3 | 3 |
| 2019 2 | 0 | 13 | 13 |
| 2019 1 | 0 | 2 | 2 |
| 2018 12 | 0 | 19 | 19 |
| 2018 11 | 0 | 5 | 5 |
| 2018 10 | 0 | 19 | 19 |
| 2018 2 | 8 | 0 | 8 |
| 2018 1 | 14 | 1 | 15 |
| 2017 12 | 9 | 0 | 9 |
| 2017 11 | 28 | 0 | 28 |
| 2017 10 | 20 | 1 | 21 |
| 2017 9 | 24 | 2 | 26 |
| 2017 8 | 19 | 3 | 22 |
| 2017 7 | 26 | 2 | 28 |
| 2017 6 | 63 | 9 | 72 |
| 2017 5 | 25 | 2 | 27 |
| 2017 4 | 18 | 2 | 20 |
| 2017 3 | 16 | 29 | 45 |
| 2017 2 | 20 | 12 | 32 |
| 2017 1 | 16 | 4 | 20 |
| 2016 12 | 33 | 8 | 41 |
| 2016 11 | 40 | 8 | 48 |
| 2016 10 | 60 | 18 | 78 |
| 2016 9 | 52 | 6 | 58 |
| 2016 8 | 30 | 2 | 32 |
| 2016 7 | 14 | 1 | 15 |
| 2016 6 | 18 | 3 | 21 |
| 2016 5 | 21 | 15 | 36 |
| 2016 4 | 20 | 19 | 39 |
| 2016 3 | 25 | 14 | 39 |
| 2016 2 | 36 | 12 | 48 |
| 2016 1 | 9 | 11 | 20 |
| 2015 12 | 16 | 5 | 21 |
| 2015 11 | 31 | 3 | 34 |
| 2015 10 | 22 | 4 | 26 |
| 2015 9 | 16 | 5 | 21 |
| 2015 8 | 43 | 7 | 50 |
| 2015 7 | 42 | 1 | 43 |
| 2015 6 | 29 | 4 | 33 |
| 2015 5 | 31 | 2 | 33 |
| 2015 4 | 31 | 3 | 34 |
| 2015 3 | 29 | 5 | 34 |
| 2015 2 | 29 | 0 | 29 |
| 2015 1 | 31 | 9 | 40 |
| 2014 12 | 50 | 5 | 55 |
| 2014 11 | 32 | 8 | 40 |
| 2014 8 | 2 | 0 | 2 |
| 2014 7 | 1 | 0 | 1 |
| 2014 6 | 0 | 1 | 1 |
| 2014 5 | 2 | 0 | 2 |
| 2013 6 | 1 | 0 | 1 |
| 2013 5 | 3 | 0 | 3 |
Show all
